Masitinib in Refractory Active Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to
methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid
arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least
one biologic drug if patients previously failed methotrexate or to 3. methotrexate in
combination with any DMARD including biologic drugs.